Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: Correlation with drug sensitivity against 5-fluorouracil

Cancer Letters

Volumn 252, Issue 2, 2007, Pages 307-313

  Kodera, Yasuhiro ^a   Ito, Seiji ^b   Fujiwara, Michitaka ^a   Mochizuki, Yoshinari ^b   Nakayama, Goro ^a   Ohashi, Norifumi ^a   Koike, Masahiko ^a   Yamamura, Yoshitaka ^b   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemosensitivity test; Histoculture drug response assay; Orotate phosphoribosyltransferase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; DNA; DNA PRIMERS; FLUOROURACIL; GENE EXPRESSION; HUMANS; PARAFFIN EMBEDDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 34249289352     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.006     Document Type: Article

References (28)

1. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355 (2006) 11-20
2. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345 (2001) 725-730
3. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., and Fleig W.E. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24 (2006) 2903-2909
4. Samson D.J., Seidenfeld J., Ziegler K.N., and Aronson N. Chemotherapy sensitivity and resistance assays: A systematic review. J. Clin. Oncol. 22 (2004) 3618-3630
5. Furukawa T., Kubota T., and Hoffman R.M. Clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1 (1995) 35-311
6. Kubota T., Egawa T., Otani Y., Furukawa T., Saikawa Y., Yoshida M., et al. Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination. Anticancer Res. 23 (2003) 583-588
7. Suda S S., Akiyama S., Sekiguchi H., Kasai Y., Ito K., and Nakao A. Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg. Today 32 (2002) 477-481
8. Iwahashi M., Nakamori M., Nakamura M., Noguchi K., Ueda K., Nakatani Y., et al. Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer. Anticancer Res. 25 (2005) 3453-3460
9. Kakimoto M., Uetake H., Osanai T., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett. 223 (2005) 103-111
10. Kanasugi M., Aoki D., Suzuki H., Susumu N., Nakata S., Horiuchi M., et al. Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. Int. J. Gynecol. Cancer 16 (2006) 409-415
11. Danenberg P.V. Thymidylate synthase - a target enzyme in cancer chemotherapy. Biochem. Biophys. Acta 473 (1977) 73-92
12. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47 (1987) 2203-2206
13. Peters G.J., Laurensse E., Leyva A., Lankelma J., and Pinedo H.M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 46 (1986) 20-28
14. Ma T., Zhu Z.-G., Ji Y.-B., Zhang Y., Yu Y.-Y., Liu B.-Y., et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine. World J. Gastroenterol. 10 (2004) 172-176
15. Toriumi F., Kubota T., Saikawa Y., Yoshida M., Otani Y., Watanabe M., et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA levels as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 24 (2004) 2455-2463
16. Ishikawa Y., Kubota T., Otani Y., Watanabe M., Teramoto T., Kumai K., et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn. J. Cancer Res. 91 (2000) 105-112
17. Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., Nihei Z., et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin. Cancer Res. 9 (2003) 786-791
18. Ichikawa W., Uetake H., Shirota Y., Yamada H., Takahashi T., Nihei Z., et al. Both gene expression for orotate phosphoribosyl transferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br. J. Cancer 89 (2003) 1486-1492
19. Ochiai T., Nishimura K., Noguchi H., Kitajima M., Tsukada A., Watanabe E., et al. Int. J. Cancer 118 (2006) 3084-3088
20. Adlard J.W., Richman S.D., Seymour M.T., and Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 3 (2002) 75-82
21. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin. Cancer Res. 6 (2000) 1322-1327
22. Japanese Gastric Cancer Association, Japanese Classification of Gastric Carcinoma - Second English Edition, Gastric Cancer 1 (1998) 10-24.
23. Toi M., Rahman M.A., Bando H., and Chow L.W.C. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 6 (2005) 158-166
24. Mizutani Y., Wada H., Fukushima M., Yoshida O., Nakanishi H., Li Y.N., and Miki T. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100 (2004) 723-731
25. Isshi K., Sakuyama T., Gen T., Nakamura Y., Kuroda T., Katsuyama T., and Maekawa Y. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5FU. Int. J. Clin. Oncol. 7 (2002) 335-342
26. Matsuyama R., Togo S., Shimizu D., Momiyama N., Ishikawa T., Ichikawa Y., et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response. Int. J. Cancer 119 (2006) 406-413
27. Rickardson L., Fryknas M., Dhar S., Lovborg H., Gullbo J., Rydaker M., et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer 93 (2005) 483-492
28. Inokuchi M., Uetake H., Shirota Y., Yamada H., Tajima M., and Sugihara K. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother. Pharmacol. 53 (2004) 391-396